AST and Marchesini Group Debut Pharma Tech Alliance at INTERPHEX 2026

NEW YORK, NY – April 15, 2026 – This year’s INTERPHEX event will serve as the official coming-out party for a formidable new alliance in pharmaceutical manufacturing. Following a landmark strategic partnership announced in December 2025, U.S.-based AST and Italian powerhouse Marchesini Group are set to unveil their combined strength, showcasing a new generation of technologies for producing sterile medicines. The exhibition, running from April 21 to 23, marks the first tangible demonstration of how this transatlantic collaboration aims to reshape the landscape of aseptic drug production.

The partnership merges AST's cutting-edge robotic systems with Marchesini Group's extensive portfolio, creating a comprehensive, end-to-end solution for pharmaceutical companies. The move is strategically timed, as the industry grapples with increasing demand for sterile injectables, complex biologics, and ever-stricter regulatory oversight.

A Strategic Alliance to Reshape Aseptic Manufacturing

The collaboration is more than a simple handshake agreement. In December 2025, Marchesini Group acquired a significant 44.39% equity stake in AST, cementing a deep financial and operational integration. As part of the deal, AST has been folded into the Marchesini Group's Aseptic Business Unit, joining a family of specialized companies that includes Corima, a specialist in sterile product filling, and CMP Phar.ma, a leader in automated inspection systems.

This structure is designed to create a synergistic powerhouse. AST, a recognized leader in robotic aseptic filling and closing systems, brings a highly specialized, U.S.-centric expertise to the table. This complements Marchesini's broader, globally-recognized capabilities that span the entire production line, from washing and depyrogenation to labeling and end-of-line packaging. The partnership is expected to be a boon for AST, which projected its revenues to grow from $55 million in 2025 to $70 million in 2026, a forecast likely bolstered by this new access to a global network.

"We're thrilled to be joining our partner, Marchesini Group, at INTERPHEX 2026. This year's exhibit will showcase AST as a full-service provider," commented Joe Hoff, President and CEO of AST. "In joining the Group's Aseptic Business Unit, AST is maximising our presence as the leading U.S. manufacturer, offering more access, more solutions, and more support to customers in the Americas and worldwide."

Valerio Soli, CEO of Marchesini Group, echoed this sentiment, emphasizing the strategic focus on innovation. "This partnership allows us to offer next‑generation integrated technologies and even more comprehensive support, particularly to the U.S. pharmaceutical market, which is advanced in the research and development of new therapies and requires highly reliable and innovative solutions," Soli stated.

Targeting the High-Stakes US Market

The partnership’s immediate focus is squarely on the United States. North America remains the largest single market for pharmaceutical equipment, driven by a highly advanced R&D ecosystem and significant investment in onshore manufacturing capacity. However, it is also one of the most demanding, with the U.S. Food and Drug Administration (FDA) enforcing rigorous standards for sterile drug production. In 2025 alone, the FDA issued over 110 warning letters related to manufacturing deficiencies, underscoring the critical need for reliable, compliant, and technologically advanced equipment.

The AST-Marchesini alliance is perfectly positioned to address this need. By combining AST's strong U.S. presence and expertise in cGMP-compliant robotics with Marchesini's vast European engineering experience, the partners can offer a robust, integrated solution that speaks directly to the challenges faced by American pharmaceutical manufacturers. The goal is to provide a single, trusted source for equipment that minimizes risk, enhances product safety, and streamlines the complex process of bringing sterile therapies to market.

The Future on Display: Robotics and Automated Inspection

At INTERPHEX Booth #2501, the theoretical benefits of the partnership will become concrete. The companies will showcase two key technologies that exemplify their combined vision for the future of sterile manufacturing.

First is AST's GENiSYS® R, a flexible robotic system for aseptic filling and closing. This machine is a game-changer for the rapidly growing field of personalized medicine, including cell and gene therapies, which often rely on small-batch production. The GENiSYS® R can seamlessly process vials, syringes, and cartridges on a single platform, drastically reducing changeover time. Its core innovation lies in its use of robotics to perform tasks within a pristine, isolated environment, minimizing human interaction—the primary source of contamination in aseptic processes. Advanced in-process controls that can measure fill volume on 100% of containers further enhance quality and maximize the yield of valuable drug products.

Alongside it will be the NSY 200 from Marchesini Group's CMP Phar.ma. This automated, hands-free inspection system for syringes tackles another critical bottleneck in production. The machine robotically handles syringes, feeding them into a high-speed inspection tunnel where up to 10 different stations use sophisticated machine vision to check for particles, fill levels, stopper placement, and glass defects. It can even perform high-voltage leak detection to ensure container integrity. This level of automation is crucial in a market where fully automated inspection systems are expected to hold over 41% of the market share in 2026, driven by the need to eliminate human subjectivity and error from quality control.

Navigating a Competitive and Growing Landscape

The strategic union of AST and Marchesini Group is not happening in a vacuum. The global pharmaceutical manufacturing equipment market is booming, projected to grow from $21.24 billion in 2026 to over $30 billion by 2032. The sub-market for aseptic filling machines alone is forecasted to double in value by 2035, while the pharmaceutical inspection machine market is expanding at a compound annual growth rate of over 10%.

This growth has attracted fierce competition from major players like GEA Group, Syntegon Technology, and Bausch + Ströbel. In this crowded field, the AST-Marchesini partnership seeks to differentiate itself by offering a uniquely integrated, end-to-end portfolio. While competitors may offer best-in-class individual machines, this alliance promises a seamless ecosystem of equipment designed to work together, from the initial filling to the final inspection. This integrated approach is a powerful proposition for pharmaceutical companies looking to build efficient, compliant, and scalable production lines for the next generation of sterile medicines. The showcase at INTERPHEX 2026 will be the industry’s first real look at how this new powerhouse plans to deliver on that promise.